SavedAdd your journal

Journals / MN Kardiyoloji / 2017 / Cilt: 24 - Sayı: 3

Non-Statin LDL Cholesterol Lowering Drugs

Statin Dışı LDL Kolesterol Düşürücü Ajanlar

İrem Müge AKBULUT
Adalet GÜRLEK
ÇETİN EROL
Pages
127–134
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, non-statin hypolipidemic agents will be reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:High LDL cholesterol levels is one of the most important risk factors for cardiovascular diseases.
📊
Key Findings & Data:As a result, statins are the leading agents for both primary and secondary prevention of the cardiovascular diseases.
💡
Conclusion & Impact:In this paper, non-statin hypolipidemic agents will be reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

High LDL cholesterol levels is one of the most important risk factors for cardiovascular diseases. As a result, statins are the leading agents for both primary and secondary prevention of the cardiovascular diseases. However, it is not always possible to reach the LDL choles-terol treatment goals with statin monotherapy. Statin intolerance and some side effects of statins also limit the use of statins, prevent-ing to reach the LDL cholesterol treatment goals. As a result, in some situations, non-statin hypolipidemic agents may be necessary to ensure the effective LDL cholesterol fall. In this paper, non-statin hypolipidemic agents will be reviewed.

Özet

Düşük yoğunluklu lipoprotein yüksekliği, kardiyovasküler hastalıklar için en önde gelen risk faktörlerinden biridir. Bu nedenle kardiyo-vasküler hastalıkların gerek primer, gerekse sekonder korunmasında en önemli ajanların başında statinler gelir. Öte yandan bazı du-rumlarda statin tedavisi, hedef LDL kolesterol düzeylerine ulaşmak için tek başına yeterli olamamaktadır. Statin intoleransı ve bazı yan etkiler ise, statin kullanımını kısıtlayarak hedef LDL kolesterol düzeylerine ulaşılmasını engelleyen durumlardır. Bu nedenle bazı durum-larda, etkin LDL kolesterol düşüşü sağlayabilmek için, statin dışı hipolipidemik ajanların kullanımı gerekli olabilmektedir. Bu yazıda, sta-tin dışı LDL kolesterol düşürücü ajanlar gözden geçirilecektir.

🔖

Cite This Article

AKBULUT, İ. M., GÜRLEK, A., EROL, Ç. (2017). Non-Statin LDL Cholesterol Lowering Drugs. MN Kardiyoloji, Cilt: 24 - Sayı: 3, 127–134. https://ajindex.com/articles/297345

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl 2013;14:67-70. 48. Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on re-gression of coronary atherosclerosis in patients with famil-ial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999;144;409-17. 47. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93;1826-35. 46. Thompson GR, Maher VM, Matthews S et al. Familial hy-percholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345; 811-6. 45. Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:220-7. 44. Keller C. LDL-apheresis in homozygous LDL-receptor-defec-tive familial hypercholesterolemia: the Munich experience. Atheroscler Suppl 2009;10;21-6. 43. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br. Med J 1985;291;1671-3. 42. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitroefficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs 1993; 17;640-52. 41. Thompson GR, Lowenthal R, Myant R. Plasma exchange in the management of homozygous familial hypercholestero-laemia. Lancet 1975; 1208-11. 40. Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine 2016; 52:187–193. 39. Santos RD, Duell PB, East Cet al. Long-term efficacy and safety of mipomersen in patients with familial hypercho-lesterolaemia: 2-year interim results of an open-label ex-tension. Eur Heart J 2015; 36(9):566-75. 38. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B syn-thesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-92. 37. Raal FJ, Santos RD, Blom DJ, et al. Mipome